Toda, Katsuhiro, Kimura, Hiroaki · Hiroshima journal of medical sciences · 2006
This case report describes one 28-year-old man with ME/CFS who was treated with a medication called Neurotropin (four tablets daily). His fatigue and widespread pain began improving within a week, and his sleep, focus, and memory improved within two weeks. He stopped taking the medication after 11 weeks and remained symptom-free for at least 5 months afterward.
ME/CFS lacks FDA-approved treatments, and anecdotal reports of symptomatic improvement with novel therapies merit documentation. This case suggests Neurotropin may warrant further investigation in controlled clinical trials, though it remains largely unknown in Western medicine and requires replication before clinical recommendations can be made.
This single case report cannot establish causation, efficacy, or safety of Neurotropin for ME/CFS. The natural history of CFS includes variable disease courses with spontaneous improvement; without a control group, placebo effect, or baseline disease trajectory data, it is impossible to determine whether the patient's improvement resulted from the medication or other factors. Results from one patient cannot be generalized to the broader ME/CFS population.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.